News
CAPR
5.04
+4.56%
0.22
Capricor Therapeutics Price Target Maintained With a $40.00/Share by HC Wainwright & Co.
Dow Jones · 4h ago
HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $40 Price Target
Benzinga · 5h ago
Optimistic Outlook for Capricor Therapeutics: Buy Rating Affirmed Amid Regulatory Progress and Strong Financial Position
TipRanks · 6h ago
Immutep, Capricor Therapeutics, Cyclacel Pharmaceuticals among healthcare movers
Immutep, Capricor Therapeutics, Cyclacel Pharmaceuticals among healthcare movers. S&P 500 Health Care Sector -0.08% to 1644.11. Pharmaceuticals, Biotechnology & Life Science contributes 58% to the index.
Seeking Alpha · 1d ago
CAPRICOR THERAPEUTICS INC: GRANTED SUBSEQUENT TYPE-B CLINICAL MEETING WITH FDA IN Q2 TO CONTINUE TO DISCUSS PATHWAY TO BLA
Reuters · 1d ago
CAPRICOR THERAPEUTICS ANNOUNCES POSITIVE TYPE-B MEETING WITH FDA FOR CAP-1002 PROGRAM FOR DUCHENNE MUSCULAR DYSTROPHY
Reuters · 1d ago
CAPRICOR THERAPEUTICS: FDA FEEDBACK SUPPORTS REQUESTS FOR PRE-BLA MEETING,SUBSEQUENT ROLLING BLA SUBMISSION FOLLOWING UPCOMING Q2 TYPE-B FDA MEETING
Reuters · 1d ago
Edgewise gets EU orphan drug status for muscular dystrophy drug
Edgewise gets EU orphan drug status for muscular dystrophy drug. Edgewise Therapeutics has received orphan drug designation from EU regulators for its drug candidate sevasemten. The drug candidate is in the treatment of Becker muscular dy Strophy and Duchenne muscular dystrophy.
Seeking Alpha · 2d ago
Weekly Report: what happened at CAPR last week (0415-0419)?
Weekly Report · 3d ago
Weekly Report: what happened at CAPR last week (0408-0412)?
Weekly Report · 04/15 12:06
Weekly Report: what happened at CAPR last week (0401-0405)?
Weekly Report · 04/08 12:13
Solid Biosciences gets FDA rare pediatric disease status for DMD therapy
Healthcare Solid Biosciences gets FDA rare pediatric disease status for DMD therapy. SGT-003 for the treatment of Duchenne muscular dystrophy. The company expects the first patient in a Phase 1/2 study for the therapy to be dosed in Q2.
Seeking Alpha · 04/01 14:17
Weekly Report: what happened at CAPR last week (0325-0329)?
Weekly Report · 04/01 12:09
Weekly Report: what happened at CAPR last week (0318-0322)?
Weekly Report · 03/25 12:13
Canopy Growth, Capricor Therapeutics, GT Biopharma among healthcare movers
Healthcare On the Move: Canopy Growth, Capricor Therapeutics, GT Biopharma among healthcare movers. S&P 500 Health Care Sector +0.23% to 1703.09. Pharmaceuticals, Biotechnology & Life Science contributes 58% to index.
Seeking Alpha · 03/22 14:00
Weekly Report: what happened at CAPR last week (0311-0315)?
Weekly Report · 03/18 12:11
Catalyst announces US launch of Duchenne drug Agamree
Healthcare Catalyst announces US launch of Duchenne drug Agamree in the U.S. For the treatment of muscular dystrophy. The therapy was approved by the FDA in October. Other drugmakers with DMD therapies in development or on the market include Roche and Pfizer.
Seeking Alpha · 03/13 17:46
Capricor Therapeutics, Inc. Is Worried About This – Should You Be Worried Too?
TipRanks · 03/12 06:01
Weekly Report: what happened at CAPR last week (0304-0308)?
Weekly Report · 03/11 12:06
Can Capricor (CAPR) Climb 261.27% to Reach the Level Wall Street Analysts Expect?
NASDAQ · 03/07 14:55
More
Webull provides a variety of real-time CAPR stock news. You can receive the latest news about Capricor Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About CAPR
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. The Company leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases.